Norges Bank
IRLA

Norges Bank’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Norges Bank’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-50
Closed -$463K – 2157
2020
Q2 		$463K Buy
+50
New +$458K ﹤0.01% 2052

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $31.9B AUM 28.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank's IRLA Position: Q3 2020 in Review

Norges Bank sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q3 2020, closing a stake of 50 shares — an estimated $463K sold.

Norges Bank first reported a position in IRLA in Q2 2020 and held it in 1 quarter. The position peaked at $463K in Q2 2020. 79 funds tracked by Wall St. Rank hold IRLA as of Q3 2020.

  • Norges Bank reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Norges Bank sold 50 IRulya Therapeutics Inc. Common Stock shares in Q3 2020, an estimated $463K.
  • Norges Bank first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Norges Bank's IRulya Therapeutics Inc. Common Stock position peaked at $463K in Q2 2020.
  • 79 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q3 2020.

Based on Norges Bank's 13F filing for Q3 2020, filed 10 Nov 2020.